Heron Therapeutics, Inc. (HRTX) Social Stream
Featured Post From StockTwits About HRTX
$HRTXINDpharmD, published August 13, 2021
Jefferies Financial Group analyst K.
Shi now expects that the biotechnology company
will post earnings of (S0.57) per share for the
quarter down from their prior estimate of (S0.52).
Jefferies Financial Group has a "Buy" rating and a
S25.00 price target on the stock.
JefferiesFinancial Group also issued estimates for Heron Therapeutics' Q4 2021 earnings at (s0.54) EPS,
FY2021 earnings at (2.31 )
EPS, FY2022 earnings at (1.74) EPS,
FY2023 earnings at(0.86) EPS,
FY2024 earnings at (0.02) EPS and
FY2025 earninas at $1.11 EPS.
Expected to lose ~100M in 2021 q2/q3, 174M in 22, 86M in 23. Breakeven in 24 and profitability in 25.
Heron has about 300M in cash/accounts receivable. Total expected burn to profitability about 350M. They might raise another 100 to 150M at some point which is essentially $1 per share. However I think it's more likely they try for an EU licensing deal that provides upfront and milestone payments.
12mo PT 25 per jefferies. Avg 33 High $60.